Also trades as: 0I0X.L (LSE) · $vol 0M
CDXS NASDAQ
Codexis, Inc.
1W: +3.0%
1M: -8.1%
3M: -48.9%
YTD: -15.5%
1Y: -45.6%
3Y: -12.3%
5Y: -94.7%
$1.36
+0.00 (+0.00%)
Weekly Expected Move ±5.5%
$1
$1
$1
$1
$2
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
7 relationships5
As Filer
counterparties named
2
As Counterparty
mentioned by others
3
Rel. Types
2021-05-07
Earliest Filing
2024-11-21
Latest Filing
customer: 3
acquirer: 1
partner: 1
Counterparties (Filed by CDXS)
5 relationshipsCompanies named in CDXS's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Nestlé | — | acquirer | Acquired interests in CDX-7108 and associated IP from Codexis, Inc. | 2023-12-27 | View |
| Vaxcyte, Inc. | PCVX | customer | Assigned lease obligations and premises from Codexis, Inc. | 2023-09-07 | View |
| Pfizer Inc. | PFE | customer | Agreement for Codexis to supply proprietary enzyme CDX-616 for use in manufacturing Pfizer's PAXLOVID product. | 2022-07-14 | View |
| Merck, Sharp & Dohme Corp. | MRK | customer | Amendment to Sitagliptin Catalyst Supply Agreement extending term to December 31, 2026 | 2021-09-09 | View |
| Piper Sandler & Co. | PIPR | partner | Sales agent for the Company's at-the-market equity offering program. | 2021-05-07 | View |
Mentioned As Counterparty
2 mentionsOther companies that named CDXS in their SEC 8-K filings.
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-08-11 | Earnings Release; Exhibits | View | |
| 2026-07-27 | Other Events; Exhibits | View | |
| 2026-07-23 | Earnings Release; Other Events | View | |
| 2026-06-22 | Shareholder Vote | View | |
| 2026-05-07 | Earnings Release; Exhibits | View | |
| 2026-04-14 | Officer/Director Change | View | |
| 2026-03-11 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-11-06 | Results of Operations and Financial Condition; Costs Associated with Exit or Disposal Activities; De | View | |
| 2025-08-13 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-06-11 | Departure/Election of Directors; Appointment of Officers; Submission of Matters to a Vote of Securit | View | |
| 2025-05-14 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-04-09 | Departure/Election of Directors; Appointment of Officers; Regulation FD Disclosure; Financial Statem | View | |
| 2025-03-31 | Departure/Election of Directors; Appointment of Officers | View | |
| 2025-02-27 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-01-16 | Departure/Election of Directors; Appointment of Officers | View | |
| 2024-11-12 | Departure/Election of Directors; Appointment of Officers; Amendments to Articles of Incorporation or | View | |
| 2024-10-31 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2024-10-22 | Departure/Election of Directors; Appointment of Officers | View | |
| 2024-10-02 | Departure/Election of Directors; Appointment of Officers | View | |
| 2024-05-02 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR